Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
Medartis Holding AG paidCHF0.0 Mil more to buy back shares than it received from issuing new shares.
It receivedCHF20.0 Mil from issuing more debt.
It paidCHF0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedCHF0.0 Mil from paying cash dividends to shareholders.
It spentCHF1.6 Mil on other financial activities.
In all, Medartis Holding AGearnedCHF18.5 Mil on financial activities for the
six
months ended in Dec. 2025.
Medartis Holding AG (XSWX:MED) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Medartis Holding AG's issuance of stock for the
six
months ended in Dec. 2025 was CHF0.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Medartis Holding AG's repurchase of stock for the
six
months ended in Dec. 2025 was CHF0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Medartis Holding AG's net issuance of debt for the
six
months ended in Dec. 2025 was CHF20.0 Mil.
Medartis Holding AG receivedCHF20.0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Medartis Holding AG's net issuance of preferred for the
six
months ended in Dec. 2025 was CHF0.0 Mil.
Medartis Holding AG paidCHF0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Medartis Holding AG's cash flow for dividends for the
six
months ended in Dec. 2025 was CHF0.0 Mil.
Medartis Holding AG receivedCHF0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Medartis Holding AG's other financing for the
six
months ended in Dec. 2025 was CHF-1.6 Mil.
Medartis Holding AG spentCHF1.6 Mil on other financial activities.
Medartis Holding AG Cash Flow from Financing Related Terms
Medartis Holding AG Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Medartis Holding AG's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medartis Holding AG Cash Flow from Financing Chart
Medartis Holding AG Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Medartis Holding AG's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF6.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of CHF6.8 Mil mean?
Medartis Holding AG (XSWX:MED) has a Cash Flow from Financing of CHF6.8 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Medartis Holding AG and its competitors.
Is Medartis Holding AG's Cash Flow from Financing too high?
Medartis Holding AG's current Cash Flow from Financing is CHF6.8 Mil. Overall, Medartis Holding AG has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medartis Holding AG's Cash Flow from Financing compare to ABT and SYK?
Medartis Holding AG's Cash Flow from Financing of CHF6.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Medartis Holding AG and its competitors. Medartis Holding AG's current Cash Flow from Financing is CHF6.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medartis Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Medartis Holding AG (XSWX:MED) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF107.08, compared to a current price of CHF91.20 — trading 14.8% below its estimated fair value. The current Cash Flow from Financing is CHF6.8 Mil. Medartis Holding AG's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Medartis Holding AG (XSWX:MED), the current Cash Flow from Financing is CHF6.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medartis Holding AG (XSWX:MED) Overvalued in 2026?
Based on GuruFocus' analysis, Medartis Holding AG stock appears to be undervalued.
The current stock price of CHF91.20 is trading 14.8% below its estimated GF Value™ of CHF107.08.
GuruFocus considers Medartis Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:MED:
Cash Flow from Financing: CHF6.8 Mil
GF Value™: CHF107.08 vs. price of CHF91.20 (14.8% below fair value)
No single metric tells the full story. See the XSWX:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from Europe, Middle East and Africa (EMEA) and also has a presence in North America, Asia Pacific, and Latin America.
86GF Score
Get the complete analysis for XSWX:MED
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MED has been successfully added to your 
